Gerald Friedland, MD

• A David Paltiel
• Ajay Malhotra
• Alison Galvani
• Anita Huttner
• Anthony Moll
• Daniel Zelterman
• David Fiellin
• David Vlahov
• E. Jennifer Edelman
• Fangyong Li
• Frederick Altice
• Gregg Gonsalves
• James Shepherd
• Jeffrey Topal
• Jeffrey Townsend
• Joseph Lucien Goulet
• Julia Shi
• Laurie Andrews
• Luke Davis
• Lydia Aoun-Barakat
• Maricar Malinis
• Marie-Louise Landry
• Mark Russi
• Merceditas Villanueva
• Michael Kozal
• Michael Virata
• Onyema Ogbuagu
• Patrick G. O'Connor
• Peter Ellis
• Peter Jatlow
• Robert Bruce
• Sandra Springer
• Sarah Christie
• Sheela Shenoi
• Sheldon Campbell
• Sten H. Vermund
• Tassos C. Kyriakides
• Veronika Shabanova
• Yanhong Deng

Acquired Immunodeficiency Syndrome; Africa, Southern; Epidemiology; HIV; Public Health; Tuberculosis; Global Health; Anti-Retroviral Agents; Extensively Drug-Resistant Tuberculosis; Infectious Disease Medicine; Geographicals

Global Health; HIV/AIDS; Infectious Diseases; Health Equity, Disparities, Social Determinants and Justice

• Timing of initiation of antiretroviral drugs during tuberculosis therapy.Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of antiretroviral drugs during tuberculosis therapy. The New England Journal Of Medicine 2010, 362:697-706.
• Averting epidemics of extensively drug-resistant tuberculosis.Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, Gandhi NR, Moll A, Moodley P, Sturm AW, Galvani AP. Averting epidemics of extensively drug-resistant tuberculosis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106:7672-7.
• HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality.Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. American Journal Of Respiratory And Critical Care Medicine 2010, 181:80-6.
• Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa.Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PloS One 2012, 7:e31786.
• Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug And Alcohol Dependence 2011, 118:326-34.
• Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts.Shenoi SV, Escombe AR, Friedland G. Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2010, 50 Suppl 3:S231-7.
• Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial.Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease : The Official Journal Of The International Union Against Tuberculosis And Lung Disease 2014, 18:147-54.
• A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection.Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. The New England Journal Of Medicine 1989, 320:545-50.
• Clinical care in the AIDS epidemic.Friedland GH. Clinical care in the AIDS epidemic. Daedalus 1989, 118:59-83.
• Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus.Feingold AR, Vermund SH, Burk RD, Kelley KF, Schrager LK, Schreiber K, Munk G, Friedland GH, Klein RS. Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. Journal Of Acquired Immune Deficiency Syndromes (1999) 1990, 3:896-903.
• Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.Frankel RE, Virata M, Hardalo C, Altice FL, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 1996, 23:577-84.
• Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease.Wetherill PE, Landry ML, Alcabes P, Friedland G. Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. Journal Of Acquired Immune Deficiency Syndromes And Human Retrovirology : Official Publication Of The International Retrovirology Association 1996, 12:33-7.
• The era of adherence to HIV therapy.Altice FL, Friedland GH. The era of adherence to HIV therapy. Annals Of Internal Medicine 1998, 129:503-5.
• Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (London, England) 1999, 13:957-62.
• Antiretroviral prophylaxis of health care workers at two urban medical centers.Russi M, Buitrago M, Goulet J, Calello D, Perlotto J, van Rhijn D, Nash E, Friedland G, Hierholzer W. Antiretroviral prophylaxis of health care workers at two urban medical centers. Journal Of Occupational And Environmental Medicine / American College Of Occupational And Environmental Medicine 2000, 42:1092-100.
• Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy.Andrews L, Friedland G. Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy. Infectious Disease Clinics Of North America 2000, 14:901-28.
• Trust and the acceptance of and adherence to antiretroviral therapy.Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. Journal Of Acquired Immune Deficiency Syndromes (1999) 2001, 28:47-58.
• Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study.Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O'Connor PG, Selwyn PA. Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine (1982) 2002, 55:235-46.
• The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects.Rainey PM, Friedland GH, Snidow JW, McCance-Katz EF, Mitchell SM, Andrews L, Lane B, Jatlow P. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. The American Journal On Addictions / American Academy Of Psychiatrists In Alcoholism And Addictions 2002, 11:66-74.
• The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2002, 34:1115-21.
• The place of prevention in HIV clinical care: a roundtable discussion.O'Rourke M, Auerbach J, del Rio C, Dooley S, Friedland G, Ridzon R. The place of prevention in HIV clinical care: a roundtable discussion. AIDS Clinical Care 2002, 14:49-53, 58.
• A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18:699-704.
• Report on the XIV International AIDS Conference.Abdool Karim SS, Currier J, del Rio C, Feinberg J, Friedland GH, Sax PE, Zuger A. Report on the XIV International AIDS Conference. AIDS Clinical Care 2002, 14:77-85.
• Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users.Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2003, 80:416-27.
• Antiretroviral treatment and research in resource-poor countries.Pawinski R, Bobat R, Friedland G, Jeena P, Lalloo U. Antiretroviral treatment and research in resource-poor countries. Lancet 2003, 361:435.
• Report from the Tenth Retrovirus Conference. Clinical trials in resource-poor settings.Friedland G. Report from the Tenth Retrovirus Conference. Clinical trials in resource-poor settings. AIDS Clinical Care 2003, 15:31-2.
• Report from the Tenth Retrovirus Conference. Tuberculosis.Friedland G. Report from the Tenth Retrovirus Conference. Tuberculosis. AIDS Clinical Care 2003, 15:32.
• Human immunodeficiency virus infection prevention: strategies for clinicians.Schreibman T, Friedland G. Human immunodeficiency virus infection prevention: strategies for clinicians. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2003, 36:1171-6.
• The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2003, 37:476-82.
• Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication.Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2004, 38 Suppl 5:S376-87.
• Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care.Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, Friedland G. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS (London, England) 2004, 18:2185-9.
• Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries.Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack C, Gandhi N, El Sadr W. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2004, 38 Suppl 5:S421-8.
• Use of total lymphocyte count for monitoring response to antiretroviral therapy.Schreibman T, Friedland G. Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2004, 38:257-62.
• Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care.Abdool-Karim SS, Abdool-Karim Q, Friedland G, Lalloo U, El-Sadr WM. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS (London, England) 2004, 18:975-9.
• Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir.McCance-Katz EF, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. The American Journal On Addictions / American Academy Of Psychiatrists In Alcoholism And Addictions 2004, 13:163-80.
• A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.Jack C, Lalloo U, Karim QA, Karim SA, El-Sadr W, Cassol S, Friedland G. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. Journal Of Acquired Immune Deficiency Syndromes (1999) 2004, 36:929-34.
• HAART for hospital health care workers--an innovative programme.Uebel K, Friedland G, Pawinski R, Holst H. HAART for hospital health care workers--an innovative programme. South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde 2004, 94:423-7.
• Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project.Fisher JD, Cornman DH, Osborn CY, Amico KR, Fisher WA, Friedland GA. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project. Journal Of Acquired Immune Deficiency Syndromes (1999) 2004, 37 Suppl 2:S78-87.
• Meeting report from the XV International AIDS Conference. Access in the developing world.Friedland GH. Meeting report from the XV International AIDS Conference. Access in the developing world. AIDS Clinical Care 2004, 16:69-70.
• Meeting report from the XV International AIDS Conference. Opportunistic infections.Friedland GH. Meeting report from the XV International AIDS Conference. Opportunistic infections. AIDS Clinical Care 2004, 16:74.
• Meeting report from the XV International AIDS Conference. Adherence.Friedland GH. Meeting report from the XV International AIDS Conference. Adherence. AIDS Clinical Care 2004, 16:74-5.
• HIV drug resistance and HIV transmission risk behaviors among active injection drug users.Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. Journal Of Acquired Immune Deficiency Syndromes (1999) 2005, 40:106-9.
• Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS (London, England) 2005, 19:1635-41.
• Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. The Journal Of Infectious Diseases 2005, 191:324-32.
• Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.Smith PF, Dicenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clinical Pharmacokinetics 2005, 44:99-109.
• Top stories of 2004. Nevirapine and efavirenz: similar efficacy, different toxicities, and better separately than combined.Friedland G. Top stories of 2004. Nevirapine and efavirenz: similar efficacy, different toxicities, and better separately than combined. AIDS Clinical Care 2005, 17:5.
• Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa.Mosam A, Cassol E, Page T, Bodasing U, Cassol S, Dawood H, Friedland GH, Scadden DT, Aboobaker J, Jordaan JP, Lalloo UG, Esterhuizen TM, Coovadia HM. Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa. AIDS (London, England) 2005, 19:441-3.
• Report from the 12th Retrovirus Conference. Adherence.Friedland GH, Nagy GS. Report from the 12th Retrovirus Conference. Adherence. AIDS Clinical Care 2005, 17:36.
• Report from the 12th Retrovirus Conference. HIV/AIDS in resource-limited settings.del Rio C, Friedland GH. Report from the 12th Retrovirus Conference. HIV/AIDS in resource-limited settings. AIDS Clinical Care 2005, 17:39-40.
• Report from the 12th Retrovirus Conference. Tuberculosis.Friedland GH. Report from the 12th Retrovirus Conference. Tuberculosis. AIDS Clinical Care 2005, 17:40-1.
• The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations.Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2005, 41:1027-34.
• Meeting notes from the 3rd IAS Conference. Male circumcision: a new prevention strategy?Friedland GH. Meeting notes from the 3rd IAS Conference. Male circumcision: a new prevention strategy? AIDS Clinical Care 2005, 17:93-4.
• Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently.Friedland GH. Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently. AIDS Clinical Care 2005, 17:98.
• Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine.McCance-Katz EF, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, Gourevitch M, Jatlow P. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. The American Journal On Addictions / American Academy Of Psychiatrists In Alcoholism And Addictions 2006, 15:23-34.
• Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2006, 43 Suppl 4:S235-46.
• Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2006, 43 Suppl 4:S224-34.
• Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice.Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. Journal Of Acquired Immune Deficiency Syndromes (1999) 2006, 41:563-72.
• Opioid dependence: rationale for and efficacy of existing and new treatments.Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2006, 43 Suppl 4:S173-7.
• A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed : Medscape General Medicine 2006, 8:72.
• Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. The Journal Of Antimicrobial Chemotherapy 2006, 58:1299-302.
• HIV medication adherence. The intersection of biomedical, behavioral, and social science research and clinical practice.Friedland GH. HIV medication adherence. The intersection of biomedical, behavioral, and social science research and clinical practice. Journal Of Acquired Immune Deficiency Syndromes (1999) 2006, 43 Suppl 1:S3-9.
• Sexual risk behaviour among HIV-positive individuals in clinical care in urban KwaZulu-Natal, South Africa.Kiene SM, Christie S, Cornman DH, Fisher WA, Shuper PA, Pillay S, Friedland GH, Fisher JD. Sexual risk behaviour among HIV-positive individuals in clinical care in urban KwaZulu-Natal, South Africa. AIDS (London, England) 2006, 20:1781-4.
• Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients.Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. Journal Of Acquired Immune Deficiency Syndromes (1999) 2006, 41:44-52.
• Report from the 13th retrovirus conference. Antiretroviral therapy in resource-limited settings.Friedland GH. Report from the 13th retrovirus conference. Antiretroviral therapy in resource-limited settings. AIDS Clinical Care 2006, 18:38.
• AIDS: the first 25 years.Friedland GH. AIDS: the first 25 years. AIDS Clinical Care 2006, 18:53-4.
• Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-80.
• Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial.Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, Friedland GH. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. Journal Of Acquired Immune Deficiency Syndromes (1999) 2006, 43 Suppl 1:S41-7.
• Development and assessment of an innovative culturally sensitive educational videotape to improve adherence to highly active antiretroviral therapy in Soweto, South Africa.Wong IY, Lawrence NV, Struthers H, McIntyre J, Friedland GH. Development and assessment of an innovative culturally sensitive educational videotape to improve adherence to highly active antiretroviral therapy in Soweto, South Africa. Journal Of Acquired Immune Deficiency Syndromes (1999) 2006, 43 Suppl 1:S142-8.
• Report from the XVI International AIDS Conference. Extensively drug-resistant TB in HIV/TB-coinfected patients in rural South Africa.Friedland GH. Report from the XVI International AIDS Conference. Extensively drug-resistant TB in HIV/TB-coinfected patients in rural South Africa. AIDS Clinical Care 2006, 18:102.
• Report from the XVI International AIDS Conference. Which antiretroviral regimen first? Data from CPCRA.Friedland GH. Report from the XVI International AIDS Conference. Which antiretroviral regimen first? Data from CPCRA. AIDS Clinical Care 2006, 18:98-9.
• Antiretroviral treatment regimen outcomes among HIV-infected prisoners.Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clinical Trials 2007, 8:205-12.
• Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2007, 45:770-8.
• Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study.Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, Moll A, Moodley P, Galvani AP, Friedland GH. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007, 370:1500-7.
• Tuberculosis and HIV coinfection: current state of knowledge and research priorities.Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. The Journal Of Infectious Diseases 2007, 196 Suppl 1:S1-3.
• Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies.Friedland G, Harries A, Coetzee D. Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. The Journal Of Infectious Diseases 2007, 196 Suppl 1:S114-23.
• Tuberculosis, drug resistance, and HIV/AIDS: a triple threat.Friedland G. Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Current Infectious Disease Reports 2007, 9:252-61.
• Managing multiple and extensively drug-resistant tuberculosis and HIV.Padayatchi N, Friedland G. Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opinion On Pharmacotherapy 2007, 8:1035-7.
• Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug And Alcohol Dependence 2007, 91:269-78.
• Tuberculosis and HIV-needed: a new paradigm for the control and management of linked epidemics.Tsiouris SJ, Gandhi NR, El-Sadr WM, Friedland G. Tuberculosis and HIV-needed: a new paradigm for the control and management of linked epidemics. MedGenMed : Medscape General Medicine 2007, 9:62.
• Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. The Journal Of Infectious Diseases 2007, 196 Suppl 3:S482-90.
• Report from the 14th Retrovirus Conference. Antiviral therapy outcomes: large survey highlights differences and similarities worldwide.Friedland GH. Report from the 14th Retrovirus Conference. Antiviral therapy outcomes: large survey highlights differences and similarities worldwide. AIDS Clinical Care 2007, 19:38.
• Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Further exploring the findings from SMART.Friedland GH. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Further exploring the findings from SMART. AIDS Clinical Care 2007, 19:83.
• Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice.Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1:115-27.
• Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care.Norton WE, Amico KR, Fisher WA, Copenhaver MM, Kozal MJ, Cornman DH, Friedland G, Fisher JD. Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care. AIDS Care 2008, 20:462-9.
• The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life.Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW. The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. Journal Of Acquired Immune Deficiency Syndromes (1999) 2008, 47:185-93.
• Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (London, England) 2008, 22:75-82.
• Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals.Mannheimer SB, Wold N, Gardner EM, Telzak EE, Huppler Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2008, 46:941-5.
• Protecting health care workers: the critical role of airborne infection control.Friedland G. Protecting health care workers: the critical role of airborne infection control. The International Journal Of Tuberculosis And Lung Disease : The Official Journal Of The International Union Against Tuberculosis And Lung Disease 2008, 12:585.
• Clinic-based intervention reduces unprotected sexual behavior among HIV-infected patients in KwaZulu-Natal, South Africa: results of a pilot study.Cornman DH, Kiene SM, Christie S, Fisher WA, Shuper PA, Pillay S, Friedland GH, Thomas CM, Lodge L, Fisher JD. Clinic-based intervention reduces unprotected sexual behavior among HIV-infected patients in KwaZulu-Natal, South Africa: results of a pilot study. Journal Of Acquired Immune Deficiency Syndromes (1999) 2008, 48:553-60.
• Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial.Burman W, Grund B, Neuhaus J, Douglas J, Friedland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C. Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. Journal Of Acquired Immune Deficiency Syndromes (1999) 2008, 49:142-50.
• Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa.Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, Pillay M, Friedland G, Sturm AW. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. The Journal Of Infectious Diseases 2008, 198:1582-9.
• Report from the 15th Retrovirus Conference. Opportunistic infections: TB, HIV and XDR TB.Friedland GH. Report from the 15th Retrovirus Conference. Opportunistic infections: TB, HIV and XDR TB. AIDS Clinical Care 2008, 20:29.
• Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105:234-9.
• Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Current Opinion In Infectious Diseases 2009, 22:11-7.
• Extensively drug-resistant tuberculosis: a new face to an old pathogen.Shenoi S, Friedland G. Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annual Review Of Medicine 2009, 60:307-20.
• Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet. Infectious Diseases 2009, 9:153-61.